Kobo Biotech Ltd vs Zenith Drugs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Kobo Biotech Ltd is ₹ 2.85 as of 27 Apr 15:30 . The P/E Ratio of Kobo Biotech Ltd is 0 as of March 2022 .The P/E Ratio of Zenith Drugs Ltd is 0 as of March 2022 . The Market Cap of Kobo Biotech Ltd is ₹ 0 crore as of March 2022 .The Market Cap of Zenith Drugs Ltd is ₹ 0 crore as of March 2022 . The Revenue of Kobo Biotech Ltd is ₹ 0.02 crore as of Jun '24 .The Revenue of Zenith Drugs Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Kobo Biotech Ltd is ₹ -0.32 crore as of Jun '24 .The EBITDA of Zenith Drugs Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Kobo Biotech Ltd is ₹ -1.33 crore as of Jun '24 .The Net Profit of Zenith Drugs Ltd is ₹ 0 crore as of Jun '24 . The Dividend Payout of Kobo Biotech Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Zenith Drugs Ltd changed from 8.99 % on March 2024 to 0 % on March 2025 . This represents a CAGR of -100.00% over 2 years .

About Kobo Biotech Ltd

Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992.
Effective 19th October, 2020, the Company's name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited.
The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu, the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US.

About Zenith Drugs Ltd

Zenith Drugs Ltd was originally incorporated on November 15, 2000 as a Private Limited Company in the name of 'Zenith Drugs Private Limited' issued by the Registrar of Companies, in the State of Madhya Pradesh, Gwalior.
Subsequently, Company was converted into Public Limited and consequently, the name of Company was changed to Zenith Drugs Limited' pursuance to issuance of a Fresh Certificate of Incorporation on September 13, 2023 by the Registrar of Companies, Gwalior. Zenith are a reputable pharmaceutical manufacturing and trading unit based out from Indore.
With a diverse portfolio of formulations, the Company is specialized in manufacturing affordable and high quality medicines to meet the needs of patients.
The Company is mainly engaged in the business of manufacturing and Trading of Medicines.

FAQs for the comparison of Kobo Biotech Ltd and Zenith Drugs Ltd

Which company has a larger market capitalization, Kobo Biotech Ltd or Zenith Drugs Ltd?

Market cap of Kobo Biotech Ltd is 6 Cr while Market cap of Zenith Drugs Ltd is 77 Cr

What are the key factors driving the stock performance of Kobo Biotech Ltd and Zenith Drugs Ltd?

The stock performance of Kobo Biotech Ltd and Zenith Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kobo Biotech Ltd and Zenith Drugs Ltd?

As of May 4, 2026, the Kobo Biotech Ltd stock price is INR ₹2.85. On the other hand, Zenith Drugs Ltd stock price is INR ₹45.35.

How do dividend payouts of Kobo Biotech Ltd and Zenith Drugs Ltd compare?

To compare the dividend payouts of Kobo Biotech Ltd and Zenith Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.